Lorna Hopcroft

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

M. Firth, Paul D. Smith, Kate F. Byth, 2017, Oncotarget.

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.

G. Lamont, D. Buttar, S. Critchlow, 2022, Journal of medicinal chemistry.

Abstract 1207: Reversing lactate-driven immunosuppression using the novel, potent and selective MCT4 inhibitor AZD0095

S. Critchlow, G. Hughes, E. Hardaker, 2019, Experimental and Molecular Therapeutics.

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

S. Barry, C. Rooney, J. Urosevic, 2023, NPJ breast cancer.

Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer

W. V. van Weerden, C. Eberlein, Jennifer I. Moss, 2024, British journal of cancer.

Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.

G. Lamont, M. P. Castaldi, Andrew X. Zhang, 2023, ACS chemical biology.